


Prolaris®

Prostate Cancer Prognostic Test

Patient guide
to the Prolaris Test
on Prostate Cancer



A COMMON DIAGNOSIS

Prostate cancer is recognized as one of the most important medical problems facing men. More than 1.4 million men were diagnosed with prostate cancer worldwide in 2022.¹ About 1 in 8 men receive a diagnosis of prostate cancer in their lifetime.²

However, most prostate cancers are slow growing, and most patients are diagnosed at an early stage with very good survival rates. Unfortunately, a portion of men will have an aggressive type of prostate cancer and have a significant risk that the prostate cancer will spread.

Therefore, it is important to assess the aggressiveness of the tumor as accurately as possible to determine the most appropriate treatment strategy.

Confused about which prostate cancer treatment is right for you?



A diagnosis of prostate cancer can make you feel like your world is collapsing and deciding what to do next can be overwhelming and confusing.

The Prolaris Prostate Cancer Prognostic Test provides personalized genomic information about how your prostate cancer is behaving, giving you and your physician confidence to choose the treatment plan that is right for you.

HOW PROLARIS BENEFITS YOU

Prolaris provides new information about your cancer that no other test can.

The Prolaris test can determine just how unique and aggressive your prostate cancer truly is.

Your Prolaris Score provides individualized information about your specific cancer to help you and your physician develop the appropriate treatment plan.



Prolaris provides answers to pressing questions




- What is the risk of my cancer spreading outside of the prostate?
- What is my risk to die from my prostate cancer?
- How should my cancer be treated
 - Am I a candidate for active surveillance?
 - Should I consider active treatment?


WHAT IS PROLARIS?

Prolaris is a gene expression test that can help your doctor predict the course of your disease.

Prolaris accurately measures the activity of specific genes that influence tumor growth and allows clear conclusions about tumor prognosis. Low gene activity is associated with a lower risk of tumor progression. High activity is associated with a higher risk.^{3,4}




This information is paired with other diagnostic tools like PSA and Gleason grading to result in your individual risk.



PROLARIS IS PERSONALIZING PROSTATE CANCER TREATMENT

The Prolaris test results come with a patient-friendly summary page designed to help you clearly and confidently understand which treatment pathway might be right for you.⁵⁻⁷





HOW PROLARIS IS PERFORMED



Better answers start with you

Prolaris is best performed on your initial biopsy and before you've made a treatment decision. To get started, first talk to your urologist to see if prognostic testing of your tumor might be appropriate.



Doctor orders the Prolaris biopsy test

The test can be requested from one of the performing pathologies in your country. The pathologist requires a sample from your existing prostate biopsy. No additional blood or biopsy samples are required.



Your genes are analyzed in the pathology lab

Using the latest gene expression technology based on tumor RNA, Prolaris measures how quickly or aggressively your cancer is growing.



Test results available in around 2 weeks

Once the results are available, they are sent to your doctor's office. Your doctor will then help you understand how your cancer is behaving, giving you confidence to take the next step.



Be prepared

Do your research on possible prostate cancer treatments, side-effects, and biomarker tests - like Prolaris. Come prepared to your oncologic consultation with any information the doctor or staff may need to see. Make sure to bring along the Prolaris patient guide.



Be open and confident

Remember that your doctor is on your side. You both want what's best for you and helping successfully manage your cancer is everyone's top priority. So just be open and honest about potential treatments or possible side-effects.



Bring your support team

The support of family members or close friends can help facilitate the conversation with your doctor and they can help act as a co-advocate for your care at your next appointment.



Polaris clarifies prostate cancer aggressiveness



Polaris is recommended by national cancer organizations and treatment guidelines⁸



Committed to making testing easy and affordable to all



References:

1. International Agency for Research on Cancer, WHO, GLOBOCAN 2024. 2. American Cancer Society, Facts & Figures 2022. 3. Cuzick, J. et al. British Journal of Cancer 2012. 4. Cuzick, J. et al. British Journal of Cancer 2015. 5. Lin, D.W. et al. Urologic Oncology: Seminars and Original Investigations. 2018. 6. Tward, J.D. et al. Journal of Clinical Oncology. 2020. 7. Tward, J.D. et al. International Journal of Radiation Oncology, Biology, Physics. 2021. 8. EAU Guidelines 2025, APCCC 2022, ASCO 2020, AUA/ASTRO 2022, DEGRO 2025, S3-Leitlinie Prostatakarzinom 2025

eurobio
SCIENTIFIC

7 Avenue de Scandinavie
ZA de Courtaboeuf
91940 Les Ulis - France
info-int@eurobio-scientific.de
www.eurobio-scientific.com



Eurobio Scientific GmbH, Marie-Curie-Straße 1
53359 Rheinbach, Germany



This in vitro diagnostic medical device is CE-marked.
For use by healthcare professionals only.



Please refer to the instructions for use.



Eurobio Scientific, the Eurobio Scientific logo are either trademarks or registered trademarks of Eurobio Scientific. Polaris and the Polaris logo are either trademarks or registered trademarks of Myriad genetics Inc. in the United States and other jurisdictions. ©2026 Eurobio Scientific GmbH

Eurobio_PROL_PT_BRO_GUIDE_07_26_EN

